Obiettivo The scope of the project is to generate a candidate drug targeting the inflammatory mediator High mobility group box 1 protein (HMGB1) to be used in treatment of stroke. The candidate drug will be validated in animal models, characterized and optimized for subsequent clinical development.Stroke remains a leading cause of death and disability throughout the world. Within EU, more than 500 000 persons die of stroke each year. Of those surviving stroke, 50% are left with physical or cognitive impairment and the total annual cost of stroke is estimated at Euro 27 billion.Stroke occurs as a consequence of hemorrhagic insult or artery occlusion due to underlying cardiovascular disease. Pivotal in beneficial treatment of stroke is instant intervention. Blood clot dissolution using recombinant tissue plasminogen activator is the only pharmacological treatment demonstrated to limit neurological damage in stroke, but is only effective for patients who present within 3 hours after stroke onset. Thus there is an unmet need for an efficacious therapy that can be administered within and beyond 3 hours to achieve neuroprotection. HMGB1, released during the cerebral ischemic event and the subsequent neuroinflammation, is a well-characterized mediator of inflammation. Beneficial effects of blocking HMGB1 is proven in preclinical stroke studies. The drug to be developed is an Affibody molecule binding to and neutralizing HMGB1. Affibody molecules are engineered proteins significantly smaller than antibodies and therefore having favorable biodistribution properties, and a history of being efficient and non-toxic in clinical trials. In this application, we describe a multidisciplinary research consortium with Europe´s leading scientists in HMGB1 research and in registry-based clinical trial and dissemination methodology. The consortium has unique potentials to bring a new treatment principle against cerebral stroke to clinical reality. Campo scientifico humanitieshistory and archaeologyhistorynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesbasic medicineneurologystroke Programma(i) FP7-HEALTH - Specific Programme "Cooperation": Health Argomento(i) HEALTH.2013.2.4.2-1 - Discovery research to reveal novel targets for cardiovascular disease treatment Invito a presentare proposte FP7-HEALTH-2013-INNOVATION-1 Vedi altri progetti per questo bando Meccanismo di finanziamento CP-FP - Small or medium-scale focused research project Coordinatore KAROLINSKA INSTITUTET Contributo UE € 1 061 198,40 Indirizzo Nobels Vag 5 17177 Stockholm Svezia Mostra sulla mappa Regione Östra Sverige Stockholm Stockholms län Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Caroline Hamilton (Mrs.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Partecipanti (5) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto AFFIBODY AB Svezia Contributo UE € 3 121 291,00 Indirizzo GUNNAR ASPLUNDS ALLE 24 171 63 Solna Mostra sulla mappa Regione Östra Sverige Stockholm Stockholms län Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Fredrik Frejd (Prof.) Collegamenti Contatta l’organizzazione Opens in new window Costo totale Nessun dato HMGBIOTECH SRL Italia Contributo UE € 576 712,00 Indirizzo PIAZZALE GORINI PAOLO 8 20133 Milano Mostra sulla mappa Regione Nord-Ovest Lombardia Milano Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Maura Casalgrandi (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato THE UNIVERSITY OF LIVERPOOL Regno Unito Contributo UE € 396 562,00 Indirizzo BROWNLOW HILL 765 FOUNDATION BUILDING L69 7ZX Liverpool Mostra sulla mappa Regione North West (England) Merseyside Liverpool Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Daniel Antoine (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato UNIVERSITA VITA-SALUTE SAN RAFFAELE Italia Contributo UE € 454 073,60 Indirizzo VIA OLGETTINA 58 20132 Milano Mostra sulla mappa Regione Nord-Ovest Lombardia Milano Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Maria Rosa Pedrazzi (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato CHARITE - UNIVERSITAETSMEDIZIN BERLIN Germania Contributo UE € 379 794,00 Indirizzo Chariteplatz 1 10117 Berlin Mostra sulla mappa Regione Berlin Berlin Berlin Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Karen Gertz (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato
